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bFGF = basic fibroblast growth factor; ER = estrogen receptor; IBC = inflammatory breast cancer; IL = interleukin; LABC = locally advanced
breast cancer; RT-PCR = reverse transcriptase-polymerase chain reaction; VEGF = vascular endothelial growth factor.
Breast Cancer Research    Vol 7 No 2 Lerebours et al.
Abstract
Inflammatory breast cancer (IBC) is both the least frequent and the
most severe form of epithelial breast cancer. The diagnosis is
based on clinical inflammatory signs and is reinforced by
pathological findings. Significant progress has been made in the
management of IBC in the past 20 years. Yet survival among IBC
patients is still only one-half that among patients with non-IBC.
Identification of the molecular determinants of IBC would probably
lead to more specific treatments and to improved survival. In the
present article we review recent advances in the molecular
pathogenesis of IBC. A more comprehensive view will probably be
obtained by pan-genomic analysis of human IBC samples, and by
functional in vitro and in vivo assays. These approaches may offer
better patient outcome in the near future.
Introduction
Inflammatory breast cancer (IBC) is diagnosed on the
basis of signs of rapid progression, such as localized or
generalized breast induration, redness and edema [1].
IBC accounts for less than 5% of all diagnosed breast
cancers [2].
IBC is the most lethal form of primary breast cancer [2].
Surgery and/or radiation therapy offers a 5-year survival
rate of less than 15% [1]. The current consensus
treatment is first-line chemotherapy with an anthracycline-
based regimen, possibly combined with a taxane,
followed by mastectomy and axillary lymph node
dissection for responders, locoregional radiotherapy and,
when appropriate, hormone therapy [3,4]. The benefits of
dose-intensive therapy and bone marrow transplantation
are not clearly established in this setting [5,6].
Maintenance adjuvant chemotherapy and new
therapeutic approaches are under study. Despite
multimodality treatments, the prognosis remains poor,
with a 3-year survival rate of only about 40%, compared
with 85% among patients with non-IBC [2,3]. These
survival data have hardly improved in the past 5 years
[3,7].
The main issue in IBC is to identify the specific pattern of
genetic changes accounting for this particular phenotype
and aggressiveness, so that we can develop more
effective targeted treatments. Little is known of these
biological and molecular mechanisms, for several reasons.
First, IBC is rare. Second, the small size of diagnostic
samples may have hindered past molecular studies. Third,
because of their similar treatment, IBC is rarely studied
separately from other forms of locally advanced breast
cancer (LABC), despite differences in age-specific
incidence rates, clinical presentation, histology, hormone
receptor status and, finally, prognosis [8–11]. The
molecular mechanisms underlying these distinct
clinicopathological entities are likely to differ, and should
thus be studied comparatively.
It is highly probable that the identification of significant
molecular changes in IBC would help with diagnosis, with
treatment response prediction, and with the development
of new therapeutic targets. As about one-third of patients
are disease-free 10 years after treatment, it would be useful
to be able to identify the two-thirds of patients requiring
intensified, prolonged, or new treatments. Most of the
prognostic parameters used in non-IBC are unfortunately
not relevant to IBC. The two main prognostic factors in
early breast cancer (stages I and II) are the number of
involved axillary nodes and the tumor size, but precise
tumor measurement is often impossible at IBC diagnosis
and most patients have axillary lymph node involvement.
The present review will focus on clinicopathological and
biological knowledge of IBC.
Clinicopathological data
Briefly, women with IBC present at a younger age than
women with non-IBC [2,8,12], with a rapidly (within
6 months) progressing inflammatory tumor associating
redness, warmth, pain, induration, and edema (also known
as ‘peau d’orange’ [i.e. ‘orange skin’]). A tumor mass may
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or may not be present. Most patients have palpable
invaded axillary lymph nodes, and up to 30% have distant
metastases at diagnosis [1].
There is disagreement over whether breast cancer with
secondary inflammatory signs qualifies as IBC. Several
authors consider that survival rates among patients with
these neglected LABCs are similar to those of women
with ‘primary inflammatory breast cancers’ [13,14].
Biological differences have been found between primary
IBC and other forms of LABC, however, and there is a
growing consensus that it is preferable to distinguish
between these two forms [8,10,15–17]. The rapid onset
of IBC in a previously healthy breast, one of the most
important characteristics of the disease, is likely to be
subtended by particular molecular alterations. For these
reasons, we feel that the term ‘secondary inflammatory
breast cancer’ is inappropriate.
Dermal lymph emboli on skin biopsy are a pathological
signature of IBC, and are generally associated with clinical
inflammatory signs. However, dermal lymphatic invasion is
identified in fewer than 75% of IBC patients, mainly
because of sampling heterogeneity [18]. IBC can be reliably
diagnosed in the absence of this pathological feature. It
should also be noted that dermal lymphatic invasion can be
associated with all breast carcinoma subtypes [19].
The percentage of infiltrating ductal carcinoma and other
histological subtypes is similar to that of non-IBC [1].
About two-thirds of IBCs are of high grade, a rate far
higher than in non-IBC [1,20]. Angiolymphatic invasion by
tumor cells is frequent in IBC, while invasion of the dermis
outside the lymphatic vessels is uncommon; this feature
distinguishes IBC from neglected secondarily inflam-
matory breast tumors [9].
Finally, the diagnosis of IBC is based on clinical signs and
is reinforced by several pathological findings.
Biological data
Hormone receptors and proliferation rates
Given its high histological grade, IBC is more frequently
estrogen-receptor (ER)-negative than non-IBC [1,10,20].
Up to 60% of IBCs lack hormone receptor expression,
whereas other forms of LABC are more likely to be ER-
positive [8,10].
Higher proliferation rates than in non-IBC, including other
forms of LABC, have been observed with several methods
(labeling index, Ki67 and S-phase fraction) [10,12,21].
Classical genes involved in non-IBC
As alterations to ERBB2,  EGFR and  TP53 can be
associated with greater breast tumor aggressiveness, their
roles in IBC have also been investigated.
In a series of 80 IBC samples, ERBB2 assessed using
Southern blotting was amplified in 41% of cases,
compared with 19% of 141 non-IBC samples [22]. Using
the same method, Prost and colleagues found that 39% of
96 IBC tumors were amplified for ERBB2, compared with
only 18% of 224 non-IBC tumors [23]. ERBB2 mRNA
expression, studied with northern blotting, is also high in
IBC (overexpressed in 61%, compared with 39% in non-
IBC) [22]. In the same study, EGFR transcripts were
observed more frequently in IBC than in non-IBC [22].
Based on real-time quantitative RT-PCR, ERBB2 mRNA
overexpression is also more frequent in IBC (36%) than in
non-IBC (26%) [17].
TP53 is mutated in approximately 30% of breast tumors.
TP53 mutations can be detected at the nucleic acid level
or at the protein level using immunohistochemistry,
although this technique is not always reliable [24]. The
TP53 gene is more frequently mutated in advanced-stage
breast cancer and/or aggressive breast cancer. Likewise,
TP53 is mutated in 30–60% of IBCs, with most mutations
located in exons 5–8, the mutational hot-spot of TP53
[17,25–27]. Based on a functional TP53 expression assay
in yeast 57% of 63 IBC samples were mutated, compared
with 37% of 27 non-inflammatory LABC samples [17].
Despite a few discrepancies [21,28], the protein
expression of the ERBB2, EGFR and TP53 genes studied
by means of immunohistochemistry is higher in IBCs than
in non-IBCs [16,21,29]. Two recently published tissue
microarray-based studies of 80 and 34 IBCs, compared
with 552 and 41 non-IBCs, respectively, confirmed these
results [12,30].
IBC is thus more likely than non-IBC to be hormone
receptor-negative, rapidly proliferative, and ERBB2-
positive, EGFR-positive, and TP53-positive.
Inflammatory genes
The rapid onset of inflammatory signs and the very high
rate of distant metastasis suggest that cytokines, growth
factors, and angiogenic factors are involved in IBC. It
appears, however, that IBC tumors produce negligible
levels of most inflammatory cytokines, including interferon
gamma, IL-1, and IL-12 [9].
We used real-time quantitative RT-PCR to quantify the
mRNA expression levels of 538 selected cancer genes in
human IBC relative to non-inflammatory LABC. None of
the best-known inflammatory cytokines (IFNγ, TNF, IL-1A,
IL-1B,  IL-8, and IL-10) was overexpressed in IBC
compared with the other samples, tending to confirm that
the inflammatory phenotype of IBC is due to dermal
lymphatic blockage by tumor cells rather than due to
infiltration by inflammatory cells [31].54
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Angiogenesis
In addition to being lymphotactic, IBC tends to be highly
angiogenic. Using the Weidner method of quantification to
study 45 IBC and 22 non-stage-matched non-IBC
samples, McCarthy and colleagues observed a significant
increase in intratumoral microvessel density in IBC [28].
Colpaert and colleagues obtained histological evidence of
intense angiogenesis in samples of 35 IBC samples
compared with 104 non-IBC samples, especially in terms
of the endothelial cell percentage [32]. This intense
angiogenesis could be due to hypoxia, as a correlation has
been observed between the hypoxia marker carbonic
anhydrase IX and endothelial cell proliferation [32].
Among nine angiogenic factors quantified by means of
RT-PCR (vascular endothelial growth factor [VEGF],
VEGFR1, VEGFR2, Ang-1, Ang-2, TIE-1, TIE-2, COX-2,
and basic fibroblast growth factor [bFGF]), the same
authors found that Ang-1, TIE-1, TIE-2, and bFGF were
strongly expressed in IBC when compared with non-IBC
[33]. High levels of VEGF, bFGF, IL-6 and IL-8 have been
found in IBC samples by another group [9].
We identified several angiogenesis-related genes (namely
VEGF, TBXA2R, PTGS2/COX2, THBD/thrombomodulin,
and ANGPT2/angiopoietin 2) that were upregulated in
IBC. However, other major angiogenic genes (VEGF2,
VEGF3, VEGF4, VEGFR1, VEGFR2, and VEGFR3) had
similar expression levels in IBC and non-IBC [31].
In vitro and in vivo models
SUM-149 and SUM-190 are two cell lines established
from primary IBC tumors [34]. Both are able to form
tumors in nude mice after mammary fat pad injection. They
have been characterized with respect to their ER, TP53,
and other classical gene expression status. These cell
lines have been studied by comparative genomic
hybridization and by differential display technology, and
the results are outlined in the next section [34,35].
Some insights into the pathogenesis of IBC have also
been obtained by studying two human IBC xenografts
designated MARY-X and WIBC-9 [36,37]. Nude mice
transplanted with MARY-X inflammatory breast carcinoma
xenografts develop tumors within lymphatics and blood
vessels, and erythema of the overlying skin, as in human
IBC [36]. Like most human IBC samples, MARY-X is ER-
negative, progesterone receptor-negative, p53-positive,
and epidermal growth factor receptor-positive, but is
Her-2/neu-negative. MARY-X has been screened for many
molecules: integrin and immunoglobulin families,
angiogenic factors of the VEGF, fibroblast growth factor,
and transforming growth factor families, and candidate
proteases and their receptors.
Only two molecules were overexpressed relative to non-
inflammatory xenografts, namely E-cadherin and MUC1
[36]. Expression of E-cadherin is thought to be ‘lost’
during malignant progression. Surprisingly, E-cadherin
overexpression and overfunction is present in MARY-X
relative to normal non-IBC cell lines and xenografts
[36,38]. This overexpression was observed using a
primary anti-E-cadherin antibody to examine the pulmonary
lymphovascular emboli spontaneously produced in MARY-
X-grafted animals [38]. Interestingly, the anti-E-cadherin
antibody caused the emboli to disappear. According to
that finding, dominant-negative E-cadherin mutants
transfected with MARY-X are weakly tumorigenic and do
not form lymphovascular emboli. Two studies have
reported E-cadherin immunoreactivity within lympho-
vascular emboli in 90–100% of human IBC samples
[16,38]. At the functional level, E-cadherin may cooperate
with sialyl-Lewis X/A-deficient MUC1 to favor passive
dissemination of tumor emboli, resulting in more frequent
and larger pulmonary metastases in MARY-X [39].
The other inflammatory breast cancer xenograft WIBC-9,
originating from a patient with IBC, frequently
metastasized and induced erythema of the overlying skin,
like MARY-X and human IBC [37]. WIBC-9 exhibits
aneuploidy and ERBB2 gene amplification, and lacks
hormone receptors. Among the four epidermal growth
factors, 18 angiogenic genes and six cytokines, only seven
genes (namely IL-8, VEGF, bFGF, angiopoietin 1, flt-1, Tie-
2 and Tie-1) are overexpressed in WIBC-9 when
compared with non-inflammatory models [37]. The
therapeutic potential of VEGF and angiopoietin pathway
blockade was explored by injecting vectors encoding
soluble Flt-1 and Tie-2 into WIBC-9. Both treatments
inhibited the growth of WIBC-9 and suppressed WIBC-9
lung metastasis [40].
Despite some discordant results, these in vitro and in vivo
models have facilitated the characterization of IBC.
Other genes involved in IBC
None of the genetic alterations cited is specific to the
inflammatory phenotype of IBC. Other genes are likely to
be specifically involved in IBC.
The two inflammatory breast cancer cell lines SUM-149
and SUM-190 have been characterized by means of
comparative genomic hybridization: frequent deletions
were observed at 3p, 8p, 11p, 11q and 13q, with gains at
1q, 7q, 8q and 17q, suggesting the presence of
candidate genes in these regions [34].
In a series of 66 human IBC samples, we found a 52%
overall rate of loss of heterozygosity using 71 micro-
satellite markers located at 21 chromosomal regions on
12 chromosomal arms associated with primary breast
cancer (1p, 3p, 6p, 6q, 7q, 8p, 9p, 11p, 11q, 16q, 17p,
and 17q), pointing to high genomic instability in55
inflammatory breast tumor cells [41]. Furthermore, 3p21-
p14, 6p, 8p22, 11q, 13q14, and 17q21 were more
frequently altered in IBC than in non-IBC. These findings
should facilitate the identification of candidate suppressor
genes in IBC.
Candidate genes may also be identified by global
analytical approaches to gene expression. By comparing
the expression of transcripts from SUM-149, actively
growing normal mammary epithelial cells, and the patients’
matched lymphocytes, van Golen and colleagues
identified 17 differentially expressed genes. Only two
genes, RhoC GTPase and the lost in inflammatory breast
cancer gene LIBC (also known as WISP3), were
respectively overexpressed and underexpressed in
inflammatory versus stage III non-inflammatory breast
tumor samples by in situ hybridization [35]. LIBC was
underexpressed in 80% of IBC samples versus 21% in
non-inflammatory LABC samples, and RhoC was
overexpressed in 90% and 36%, respectively [35].
LIBC/WISP3 appears to be a good candidate gene in
IBC: it is located at 6q22-q23, a frequently deleted region
in breast tumors, and LIBC/WISP3 seems to be a
member of the IGFBP family, already known for a role in
cancer progression [35]. Finally, functional data indicate
that LIBC/WISP3 acts as a tumor suppressor gene in the
breast, and that loss of its expression contributes to the
proliferative and invasive phenotype of IBC [42].
Using stable human mammary epithelial-RhoC trans-
fectants, van Golen and colleagues demonstrated that
RhoC GTPase is a transforming oncogene in human
mammary cells, leading to a highly invasive phenotype akin
to that seen in IBC [43]. RhoC GTPase expression seems
to be modulated by WISP3, and these two genes might
thus act in concert to give rise to IBC [44]. Using
quantitative RT-PCR, however, we found RhoC
overexpression only in three of 32 inflammatory breast
tumor samples [17].
Among the 538 selected genes that we studied by real-
time quantitative RT-PCR in IBC samples, 27 (5.0%) were
significantly upregulated compared with non-inflammatory
LABC [31]. None of the genes was downregulated. The
27 upregulated genes encoded seven transcription
factors (JUN, EGR1, JUNB, FOS, FOSB, MYCN, and
SNAIL1), four of which are components of the AP-1
transcription factor family (JUN, JUNB, FOS, and FOSB).
AP-1 has been implicated in a variety of tumoral
processes [45]. The other 20 upregulated genes encoded
growth factors (VEGF,  DTR/HB-EGF, IGFBP7, IL-6,
ANGPT2, EREG, CCL3/MIP1A, and CCL5/RANTES) or
growth factor receptors (TBXA2R, TNFRSF10A/
TRAILR1, and ROBO2), mainly involved in angiogenesis.
Finally, IBC and non-IBC showed similar expression levels
of the genes WISP3/LIBC, RhoC and  E-cadherin, a
finding that conflicts with several other reports [31].
One should be cautious in interpreting biological studies on
IBC since many of them have been performed at the RNA
level, which may not reflect the functional protein level.
Prognostic factors
By definition, patients diagnosed with IBC have at least
stage IIIB disease. Up to 30% of these patients become
long-term disease-free survivors, however, and it would be
of interest to be able to identify those patients requiring
intensified, prolonged, or novel therapies. Unfortunately,
specific prognostic factors are lacking in IBC.
Pathological factors
Although a large initial tumor size has been linked to a
poorer prognosis [46,47], this criterion would not be very
useful as a measurable tumor mass is rare in patients with
IBC. Lymph node involvement at diagnosis has also been
linked to poorer outcome [48,49]. However, physical
examination can overestimate lymph node status in up to
50% of cases and cytologic evaluation is rarely done.
In an attempt to refine prognostication in IBC, Gustave-
Roussy investigators developed a staging system named
‘Poussee Evolutive’ (PEV) based on signs of inflammation
and tumor aggressiveness [50]. At diagnosis, about one-
third of IBC patients have PEV3 tumors, with inflammation
involving the entire breast, whereas the remaining patients
(PEV2) have only localized breast inflammation (less than
50% of the breast). We sought correlations between
several molecular features, clinicopathological features,
and clinical outcome in a series of 64 IBC patients [51].
Respectively one-third and two-thirds of the 64 patients
had PEV3 tumors and PEV2 tumors. With the exception of
stage IV disease, extensive breast inflammation (PEV3) at
the first clinical examination was the main factor
associated with poor outcome, in keeping with previous
studies [48,49,51,52].
The presence of dermal lymphatic invasion, while not
necessary for diagnosis, could also be associated with
poor prognosis [18,53], but this is controversial
[1,12,46,54].
The response to chemotherapy may be the best
prognostic indicator in IBC, as in other forms of LABC and
operable breast tumors first treated with first-line
chemotherapy. The prognostic value of the response to
chemotherapy has mainly been studied in terms of clinical
characteristics. There is increasing evidence, however,
that the pathologic response, and particularly a complete
response, could predict outcome more reliably [55,56]. In
IBC, the clinical response has been correlated with
survival [48,52,57,58]. The few papers reporting
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pathological responses tend to confirm the prognostic
value of this criterion [4,59–61].
It is now recognized that IBC patients who respond to
chemotherapy are candidates for a mastectomy and
axillary lymph node dissection [4,62,63]. As in ‘not other-
wise specified’ breast tumors, lymph node involvement at
this stage has prognostic value [7,11,57].
Biological factors
Classical markers of poor outcome in breast cancer have
been thought to contribute to poor outcome in IBC too.
For example, ER negativity has been linked to poor
prognosis in inflammatory breast tumors by some authors
[1,20,52,62], but not by others [10,51].
As in non-IBC, the prognostic value of ERBB2 and TP53
is controversial [12,22,23,26]. ERBB2 amplification was
not associated with poorer outcome in a series of 67 IBC
patients, contrary to a series of 178 non-IBC patients [23].
Applying multivariate analysis to data on 24 patients with
IBC, Riou and colleagues found a positive correlation
between p53 nuclear overexpression and poor clinical
outcome [26]. In another series of 32 IBC patients, TP53
mutations were associated with large tumors and
metastases at diagnosis [25].
In a recent immunophenotypic study of 80 IBC patients
compared with 552 non-IBC controls, tissue arrays were
used to determine the protein expression of ER,
progesterone receptor, EGFR and ERBB2, MIB1, P53,
MUC1 and E-cadherin [12]. Five variables were
significantly associated with IBC in multivariate analysis:
MIB1,  ERBB2 and E-cadherin overexpression, ER
negativity, and MUC1 cytoplasmic staining. This five-gene
molecular signature of IBC was further explored for its
possible prognostic significance. The 5-year survival rates
of patients with IBC were not significantly different from
those of non-IBC controls fulfilling four or five of these
criteria. Furthermore, this non-IBC group had a
significantly worse outcome than their counterparts with
between none and three of these criteria [12].
Among 538 selected genes, we identified a three-gene
expression profile — based on MYCN, EREG, and SHH —
which discriminated subgroups of IBC patients with good
outcome, intermediate outcome, and poor outcome [31].
EREG (epiregulin) belongs to the EGF growth factor
family that binds both ERBB1 and ERBB4. SHH codes
for the most important molecule of the Hedgehog-Gli
signaling pathway. Inappropriate activation of the SHH
pathway occurs in several malignancies [64]. Although
unexpected in the context of breast tumorigenesis, MYCN
was recently identified as a major direct target of SHH
pathways [65]. This three-gene expression signature of
poor-prognosis IBC warrants validation in larger series.
Conclusions
Substantial progress has been made in our knowledge
and management of IBC in the past 20 years. In our
opinion, the most important factors are the development of
in vivo models that can be used to determine the role of
candidate genes in IBC, and the demonstration that IBC is
a disease entity distinct from other forms of LABC. There
is now a need for more comprehensive molecular analyses
of IBC, using cDNA microarrays or comparative genomic
hybridization arrays, as in non-IBC. These global
approaches will probably be more fruitful than studies
focusing on one or just a few genes. If successful, these
studies should pave the way for novel treatments that will
improve the currently dismal survival rates of patients with
IBC.
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